Equity Profile

TARS

Tarsus Pharmaceuticals, Inc.

Health CarePharmaceuticals$3.0B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Tarsus Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

N/A

Revenue Growth

Investors will be interested in any revenue figures as they reflect the company's market performance and acceptance of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TARS Q2-2026 Earnings Preview

Context

Company Snapshot

Tarsus Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for eye diseases. With a market cap of $3 billion, its work is significant in the pharmaceutical sector, particularly as it addresses unmet medical needs in ophthalmology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+14.49%

Avg Stock Reaction

-0.37%

Last Quarter Recap

In Q1 2026, Tarsus reported an EPS of -$0.16, which was a significant surprise compared to the expected -$0.46. The stock reacted negatively, declining by 0.43% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Tarsus are mixed, given the recent earnings surprises and the lack of specific guidance. Investors are uncertain about the company's ability to maintain momentum.

Bull Case

If Tarsus can continue to surprise on EPS and show signs of revenue growth, it could indicate strong demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or shows continued losses, it could raise concerns about its long-term viability and lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026, and how does it compare to analyst expectations?

Given Tarsus's history of EPS surprises, this number will be crucial for determining market sentiment.

What are the revenue figures for this quarter?

Revenue growth is essential for assessing the company's market traction and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Tarsus's ability to surprise on EPS due to its recent performance trends, which indicate a potential for recovery.

Supporting Evidence

The company has a 75% EPS beat rate in the last eight quarters, indicating a strong potential for positive surprises.

Options pricing suggests a significant move, which may reflect underlying investor sentiment not captured in consensus estimates.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Tarsus can sustain its recent performance or if it will revert to larger losses.

Bull Confirmed If

A positive EPS surprise of greater than 50% compared to expectations would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.20 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.64%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±30.6% while TARS has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (300)P/C Ratio: 0.19Puts (500)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tarsus beats expectations, history suggests a potential stock increase of around 2.83%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience a muted reaction as investors await further clarity.

Miss

Should Tarsus miss expectations, history suggests a potential decline of around 2.83%, raising concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management strategies and their effect on future profitability.
4Insights into customer feedback and product adoption rates.
5Any guidance on future quarters and expected milestones.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Tarsus Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

N/A

Revenue Growth

Investors will be interested in any revenue figures as they reflect the company's market performance and acceptance of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TARS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+14.49%

Avg Stock Reaction

-0.37%

Last Quarter Recap

In Q1 2026, Tarsus reported an EPS of -$0.16, which was a significant surprise compared to the expected -$0.46. The stock reacted negatively, declining by 0.43% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Tarsus are mixed, given the recent earnings surprises and the lack of specific guidance. Investors are uncertain about the company's ability to maintain momentum.

Bull Case

If Tarsus can continue to surprise on EPS and show signs of revenue growth, it could indicate strong demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or shows continued losses, it could raise concerns about its long-term viability and lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026, and how does it compare to analyst expectations?

Given Tarsus's history of EPS surprises, this number will be crucial for determining market sentiment.

What are the revenue figures for this quarter?

Revenue growth is essential for assessing the company's market traction and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Tarsus's ability to surprise on EPS due to its recent performance trends, which indicate a potential for recovery.

Supporting Evidence

The company has a 75% EPS beat rate in the last eight quarters, indicating a strong potential for positive surprises.

Options pricing suggests a significant move, which may reflect underlying investor sentiment not captured in consensus estimates.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Tarsus can sustain its recent performance or if it will revert to larger losses.

Bull Confirmed If

A positive EPS surprise of greater than 50% compared to expectations would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.20 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.64%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±30.6% while TARS has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (300)P/C Ratio: 0.19Puts (500)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tarsus beats expectations, history suggests a potential stock increase of around 2.83%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience a muted reaction as investors await further clarity.

Miss

Should Tarsus miss expectations, history suggests a potential decline of around 2.83%, raising concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management strategies and their effect on future profitability.
4Insights into customer feedback and product adoption rates.
5Any guidance on future quarters and expected milestones.